Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

843.60 +5.40 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. 
Via Benzinga
3 Biotech Stocks That Could Boom or Bust in Q1
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future. 
Via InvestorPlace
5 Things To Expect This Week
While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors. 
Via InvestorPlace
Analyst Ratings For Regeneron Pharmaceuticals
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter: 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi 
Via Benzinga
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have  
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Promising Results Continue to Develop Optimism in Fight Against Cancers
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types... 
Via FinancialNewsMedia
A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
Pre-open movers U.S. stock futures traded mostly lower in early pre-market trade. The Dow Jones settled higher by around 100 points on Monday after tumbling more than 1,000 points... 
Via Benzinga
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their... 
Via Benzinga
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as... 
Via Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in... 
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC 
Via Benzinga
WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge
An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc... 
Via Benzinga
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma... 
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Why JPMorgan Is Among Rob Sechan's Top Picks For 2022
With the Federal Reserve having suggested that rates are likely headed higher this year, financials have been an area of focus for investors.&... 
Via Benzinga
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: 
Via Benzinga
Market Briefing For Wednesday, Jan. 5
Rising interest rates have yet to spark overt action by the Fed nor yet to cool-off the hot real estate market. However, the Nasdaq was hit hard, presumably as the 10-year rallied. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,... 
Via FinancialNewsMedia
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica... 
Via Benzinga
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
Via Benzinga
3 Cathie Wood Stocks To Buy On The Dip
Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in... 
Via Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain
Two tests from independent labs suggest Adagio's antibody could still target omicron. 
Via Investor's Business Daily
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback